Brexit Shock Dodged by U.K. Pharma as Innovation Spurs DealsBy
Companies such as Martindale, Morningside said to explore sale
Pharma companies seek to cash out despite market volatility
As the U.K.’s vote to leave the European Union wreaks havoc on the economy, dealmaking momentum in the country’s pharmaceutical industry is showing no signs of letting up.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.